Skip to main content

Table 2 Proportion of patients with AEs (Safety Population*)

From: A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Preferred term, n (%)

Safety Population (N = 161)*

Number of patients with AEs, n (%)

94 (58.4)

Ocular AEs, n (%)

28 (17.4)

 Conjunctivitis allergic

8 (5.0)

 Conjunctivitis

7 (4.3)

 Cataract

6 (3.7)

 Asthenopia

5 (3.1)

 Conjunctival haemorrhage

5 (3.1)

 Dry eye

5 (3.1)

 Eye pain

5 (3.1)

 Ocular discomfort

5 (3.1)

 Lacrimation decreased

4 (2.5)

 Retinal hemorrhage

4 (2.5)

  1. AE adverse event, N total number of patients, n number of patients, MedDRA medical dictionary for regulatory activities, SAE serious AE
  2. *Safety population consisted of all patients who received at least 1 dose of observational medication and had at least 1 post-baseline safety assessment. AEs ≥2% have been included. Preferred terms (MedDRA v2.0) are presented by descending order of frequency